Here: highlights of a new study of the antipsychotic agent ziprasidone in bipolar spectrum disorder -- and a quick synopsis of another trial of a recently approved inhaled form of the antipsychotic loxapine in bipolar disorder and schizophrenia.
A comprehensive program had significant benefit for depression in bipolar patients living in the Netherlands. Another study highlights the poor quality of primary care for bipolar patients in one of the United States.
Media attention to bipolar and Internet-based information lead some people to decide (mistakently) that they have the condition. Correct assessment and affirming reassurance, studies snow, is what patients with mood instability want most.